Use of a Serum With the Infinite Glow® Device Improves Signs of Facial Aging: A Split-Face Case Report Using VISIA Analysis.
The combined use of a topical serum and a multi-technology device showed some improvements in facial aging signs, particularly in wrinkle reduction, but further research is needed to confirm these results.
Where it sits
this study against the rest of the matrixyl corpusSummary and findings
The study evaluated the efficacy and safety of a combined therapy using a topical serum and a multi-technology facial device in a 41-year-old woman with moderate facial aging over 12 weeks. The left hemiface received a serum containing hyaluronic acid, niacinamide, and Matrixyl, while the right hemiface received the same serum plus the device. Improvements in skin quality parameters were observed, with a notable reduction in wrinkles on the device-treated side.
Abstract
An increase in wrinkles, laxity, and dyschromia characterizes facial-skin aging. The skin is a natural barrier that prevents or limits the entry of external therapeutic compounds to the body. Enhancing the efficacy of transdermal delivery of anti-aging compounds is a key therapeutic strategy. The study aimed to evaluate the efficacy and safety of a combined therapy that included a topical anti-aging serum and a multi-technology facial device designed to improve transdermal absorption. A 41-year-old woman with moderate facial aging was treated using a split-face design for 12 weeks. Every day, the left hemiface received a hyaluronic acid-niacinamide-Matrixyl serum. In contrast, the right hemiface received the same serum plus application of a multi-therapy device that delivered red light (630 nm), galvanic current, micro-vibration, and controlled heat. Skin changes were assessed using the VISIA Skin Analysis System (Canfield Scientific, Parsippany, New Jersey) at baseline, 6, and 12 weeks. Both hemifaces showed improvement in skin quality parameters (wrinkles, texture, and UV spots). TruSkin age decreased by five years on the treated side with the device + serum and by one year on the serum-only side. Greater improvement in wrinkle reduction was observed on the device-treated side. No adverse events were reported. As a preliminary observation, combined therapy using a topical serum and a multimodal device appears safe and attenuates aging effects, particularly in reducing wrinkles. Further studies are needed to confirm these findings.
Background
This paper addresses the clinical question of how to enhance the efficacy of transdermal delivery of anti-aging compounds in facial skin. Previous studies have indicated that skin aging is characterized by increased wrinkles and laxity, and that improving the absorption of topical agents may yield better outcomes. This study is significant as it explores a combined approach to facial rejuvenation using both a topical serum and a multi-technology device.
Methods
The study employed a split-face design with a single participant, a 41-year-old woman, treated for 12 weeks. The left hemiface received a serum containing hyaluronic acid, niacinamide, and Matrixyl, while the right hemiface received the same serum plus a multi-therapy device delivering red light (630 nm), galvanic current, micro-vibration, and controlled heat. Skin changes were assessed using the VISIA Skin Analysis System at baseline, 6 weeks, and 12 weeks.
Results
The primary endpoint indicated that TruSkin age decreased by five years on the device-treated side and by one year on the serum-only side. Both hemifaces showed improvements in skin quality parameters, including wrinkles, texture, and UV spots. Greater improvement in wrinkle reduction was specifically noted on the device-treated side.
Interpretation
While the findings suggest a potential benefit of the combined therapy, the effect size may not be clinically meaningful given the small sample size and lack of a control group. The absence of adverse events is noted, but the single-subject design limits the ability to generalize these results. Further studies with larger populations and control groups are necessary to validate these preliminary observations.
Key findings
- TruSkin age decreased by five years on the treated side with the device + serum and by one year on the serum-only side.
- Greater improvement in wrinkle reduction was observed on the device-treated side.
- No adverse events were reported.
Limitations
- Single-subject design limits generalizability.
- No control group for comparison.
- Short follow-up duration of 12 weeks.